专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07645613B2 Mass spectrometry techniques for determining the status of sepsis in an individual 有权
标题翻译：用于确定个体败血症状态的质谱技术
公开(公告)号：US07645613B2
公开(公告)日：2010-01-12
申请号：US11647688
申请日：2006-12-28
申请人： Richard M. Ivey , Thomas M. Gentle, Jr. , Richard L. Moore , Michael L. Towns , Gary Siuzdak , Elizabeth J. Want , Zhouxin Shen , Nicholas Bachur, Jr. , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice
发明人： Richard M. Ivey , Thomas M. Gentle, Jr. , Richard L. Moore , Michael L. Towns , Gary Siuzdak , Elizabeth J. Want , Zhouxin Shen , Nicholas Bachur, Jr. , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice
IPC分类号： G01N24/00
CPC分类号： G01N33/6848 , C12Q1/6883 , G01N33/6803 , G01N2800/26 , Y10T436/24
摘要： Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.
摘要翻译：提供了用于确定个体败血症状态的质谱技术。将使用质谱技术从个体获取的生物样品分解的生物标志物谱与参考生物标志物谱进行比较。单个这样的比较将个体归类为属于或不属于参考群体。个体的生物标志物概况和参考生物标志物谱包括多个离子，其各自具有约100道尔顿至约1000道尔顿的质荷比。可以通过电喷雾电离质谱法以正模式检测多个离子。比较使用决定规则，例如分类树，其确定个体中败血症的状态，而不需要知道来自个体的生物标志物概况中的生物标志物的身份，并且不需要知道生物标志物的身份参考生物标志物概况。

2. 发明申请

US20080138832A1 Diagnosis of sepsis or SIRS using biomarker profiles 审中-公开
标题翻译：使用生物标志物图谱诊断败血症或SIRS
公开(公告)号：US20080138832A1
公开(公告)日：2008-06-12
申请号：US11904282
申请日：2007-09-25
申请人： Richard M. Ivey , Thomas M. Gentle , Richard L. Moore , Michael L. Towns , Nicholas Bachur , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice
发明人： Richard M. Ivey , Thomas M. Gentle , Richard L. Moore , Michael L. Towns , Nicholas Bachur , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice
IPC分类号： G01N33/53 , C12Q1/02 , G01N33/00
CPC分类号： G01N33/6803 , C12Q1/6837 , C12Q1/686 , C12Q1/6883 , C12Q2600/158 , G01N2800/26
摘要： The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.
摘要翻译：败血症的早期预测或诊断有利地允许在疾病快速进展到初始阶段之前的临床干预到更严重的阶段，例如与高死亡率相关的更严重的败血症或败血性休克。通过将个体的生物标志物表达谱与从一个或多个对照或参考群体获得的概况进行比较来实现早期预测或诊断，其可包括发生败血症的群体。识别个体生物标志物特征的特征是脓毒症发作的特征允许临床医生在单个时间点诊断从个体分离的体液的败血症发作。因此，避免在一段时间内监测患者的必要性，有利地允许在脓毒症严重症状发作之前进行临床干预。此外，因为生物标志物的表达被测定其特征，所以特定生物标志物的鉴定是不必要的。个体的生物标记谱与适当参考群的生物标志物概况的比较同样可以用于诊断个体中的SIRS。

3. 发明授权

US07632685B2 Method of predicting the onset of sepsis in SIRS-positive individuals using mass spectrometry 有权
标题翻译：使用质谱法预测SIRS阳性个体败血症发病的方法
公开(公告)号：US07632685B2
公开(公告)日：2009-12-15
申请号：US11647689
申请日：2006-12-28
申请人： Richard M. Ivey , Thomas M. Gentle, Jr. , Richard L. Moore , Michael L. Towns , Nicholas Bachur, Jr. , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice , Gary Siuzdak , Elizabeth Want , Zhouxin Shen
发明人： Richard M. Ivey , Thomas M. Gentle, Jr. , Richard L. Moore , Michael L. Towns , Nicholas Bachur, Jr. , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice , Gary Siuzdak , Elizabeth Want , Zhouxin Shen
IPC分类号： G01N24/00
CPC分类号： G01N33/6848 , C12Q1/6883 , G01N33/6803 , G01N2800/26 , Y10T436/24
摘要： Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.
摘要翻译：提供了用于确定个体败血症状态的质谱技术。将使用质谱技术从个体获取的生物样品分解的生物标志物谱与参考生物标志物谱进行比较。单个这样的比较将个体归类为属于或不属于参考群体。个体的生物标志物概况和参考生物标志物谱包括多个离子，其各自具有约100道尔顿至约1000道尔顿的质荷比。可以通过电喷雾电离质谱法以正模式检测多个离子。比较使用决定规则，例如分类树，其确定个体中败血症的状态，而不需要知道来自个体的生物标志物概况中的生物标志物的身份，并且不需要知道生物标志物的身份参考生物标志物概况。

4. 发明申请

US20070184512A1 Mass spectrometry techniques for determining the status of sepsis in an individual 有权
标题翻译：用于确定个体败血症状态的质谱技术
公开(公告)号：US20070184512A1
公开(公告)日：2007-08-09
申请号：US11647688
申请日：2006-12-28
申请人： Richard M. Ivey , Thomas M. Gentle , Richard L. Moore , Michael L. Towns , Nicholas Bachur , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice , Gary Siuzdak , Elizabeth Want , Zhouxin Shen
发明人： Richard M. Ivey , Thomas M. Gentle , Richard L. Moore , Michael L. Towns , Nicholas Bachur , Robert W. Rosenstein , James G. Nadeau , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice , Gary Siuzdak , Elizabeth Want , Zhouxin Shen
IPC分类号： C12Q1/37 , G06F19/00
CPC分类号： G01N33/6848 , C12Q1/6883 , G01N33/6803 , G01N2800/26 , Y10T436/24
摘要： Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.
摘要翻译：提供了用于确定个体败血症状态的质谱技术。将使用质谱技术从个体获取的生物样品分解的生物标志物谱与参考生物标志物谱进行比较。单个这样的比较将个体归类为属于或不属于参考群体。个体的生物标志物概况和参考生物标志物谱包括多个离子，其各自具有约100道尔顿至约1000道尔顿的质荷比。可以通过电喷雾电离质谱法以正模式检测多个离子。比较使用决定规则，例如分类树，其确定个体中败血症的状态，而不需要知道来自个体的生物标志物概况中的生物标志物的身份，并且不需要知道生物标志物的身份参考生物标志物概况。

5. 发明授权

US07645573B2 Diagnosis of sepsis or SIRS using biomarker profiles 有权
标题翻译：使用生物标志物图谱诊断败血症或SIRS
公开(公告)号：US07645573B2
公开(公告)日：2010-01-12
申请号：US10704666
申请日：2003-11-12
申请人： Richard M. Ivey , Thomas M. Gentle, Jr. , Richard L. Moore , Michael L. Towns , Nicholas Bachur, Jr. , Robert W. Rosenstein , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice
发明人： Richard M. Ivey , Thomas M. Gentle, Jr. , Richard L. Moore , Michael L. Towns , Nicholas Bachur, Jr. , Robert W. Rosenstein , Paul E. Goldenbaum , Song Shi , Donald Copertino , James Garrett , Gregory Tice
IPC分类号： C12Q1/68 , C12P19/34
CPC分类号： C12Q1/6883 , C12Q1/6837 , C12Q1/686 , C12Q2600/158 , G01N33/6893 , G01N2800/26
摘要： The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.
摘要翻译：败血症的早期预测或诊断有利地允许在疾病快速进展到初始阶段之前的临床干预到更严重的阶段，例如与高死亡率相关的更严重的败血症或败血性休克。使用分子诊断方法实现早期预测或诊断，包括将个体的生物标志物表达谱与从一个或多个对照或参考群体获得的概况进行比较，其可包括发生败血症的群体。识别个体生物标志物特征的特征是脓毒症发作的特征，允许临床医生在单个时间点从个体分离的体液诊断败血症的发作。因此，避免在一段时间内监测患者的必要性，有利地允许在严重症状发作之前进行临床干预。此外，因为生物标志物的表达被测定其特征，所以特定生物标志物的鉴定是不必要的。个体的生物标记谱与适当参考群的生物标志物概况的比较同样可以用于诊断个体中的SIRS。

6. 发明授权

US4994378A Method for reducing blood carbon dioxide background in bacterial media by the addition of micelles of saponin and a phospholipid 失效
标题翻译：通过加入皂角苷和磷脂的胶束来减少细菌培养基中血二氧化碳背景的方法
公开(公告)号：US4994378A
公开(公告)日：1991-02-19
申请号：US404475
申请日：1989-09-08
申请人： Dolores M. Berger , Paul E. Goldenbaum , Gregory Tice
发明人： Dolores M. Berger , Paul E. Goldenbaum , Gregory Tice
IPC分类号： C12Q1/04
CPC分类号： C12Q1/04
摘要： A non-ionic lytic agent, preferably saponin for reducing the background carbon dioxide produced by blood cell metabolism is used in the testing of cultures for the presence of microorganisms. The hemolytic agent saponin is combined with a phospholipid, preferably L-.alpha.-Lecithin (phosphatidylcholine), to form mixed micelles which protect saponin from the effects of heat sterilization and high blood cholesterol levels, thus maintaining the lytic activity of saponin. The phospholipid/saponin mixed micelles are added to non-radiometric culture media vials such as Bactec.RTM. NR6A, NR7A and NR8A. The media vials are used in the Bactec.RTM. NR-660 and NR-730 instruments. However, the present invention may also be used in radiometric media such as Bactec.RTM. culture vials 6, 7 and 8 for reducing background carbon dioxide levels detected in C.sup.14 radiometric instruments such as the Bactec.RTM.-460, or in other instruments designed to detect bacteria in the presence of mammalian cells by monitoring the increase in CO.sub.2 produced by the metabolizing bacteria.
摘要翻译：用于减少血液细胞代谢产生的背景二氧化碳的非离子溶解剂，优选皂苷用于微生物存在的培养物的测试中。溶血剂皂苷与磷脂，优选L-α-卵磷脂（磷脂酰胆碱）组合形成混合的胶束，其保护皂苷免受热灭菌和高血胆固醇水平的影响，从而保持皂角苷的溶解活性。将磷脂/皂角苷混合胶束加入非辐射培养基小瓶如Bactec TM NR6A，NR7A和NR8A。介质小瓶用于Bactec TM NR-660和NR-730仪器。然而，本发明也可以用于辐射介质如Bactec TM培养瓶6,7和8中，用于降低C14辐射仪器如Bactec TM -460中检测到的背景二氧化碳水平，或用于其他设计用于检测细菌的仪器在哺乳动物细胞的存在下，通过监测由代谢细菌产生的CO 2的增加。

7. 发明授权

US6130057A Method for differentiating microorganisms in a sample 有权
标题翻译：分析样品中微生物的方法
公开(公告)号：US6130057A
公开(公告)日：2000-10-10
申请号：US407638
申请日：1999-09-28
申请人： C. Michael Gosnell , Carrie A. Hughes , Paul E. Goldenbaum
发明人： C. Michael Gosnell , Carrie A. Hughes , Paul E. Goldenbaum
IPC分类号： C12N1/00 , C12Q1/04 , C12Q1/18 , C12Q1/02
CPC分类号： C12Q1/045 , Y10S435/968
摘要： Culture media for microorganisms containing blood or hemin, particularly Trypticase Soy Agar with blood, and chocolate agar, are combined with known chromogenic substrates to produce chromogenic media. Methods for preparing these chromogenic media include adding chromogenic substrates to the surface of previously prepared media, or incorporating the chromogenic substrate into the media as it is prepared. Methods for distinguishing microorganisms in a sample using these culture media are also described.
摘要翻译：用于含有血液或血红素的微生物的培养基，特别是具有血液的胰蛋白酶大豆琼脂和巧克力琼脂与已知的显色底物组合以产生显色培养基。制备这些显色培养基的方法包括将生色底物添加到先前制备的培养基的表面，或者在制备时将生色底物掺入培养基中。还描述了使用这些培养基来区分样品中微生物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式